Keros Therapeutics price target lowered to $25 from $40 at H.C. Wainwright

H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Keros Therapeutics (KROS) to $25 from $40 and keeps a Buy rating on the shares. Th firm says the early termination of the TROPOS trial due to pericardial effusions across all dose cohorts “was a clear setback for cibotercept.” However, the forthcoming dataset still matters, the analyst tells investors in a research note.